Literature DB >> 18278052

Perivascular nitric oxide gradients normalize tumor vasculature.

Satoshi Kashiwagi1, Kosuke Tsukada, Lei Xu, Junichi Miyazaki, Sergey V Kozin, James A Tyrrell, William C Sessa, Leo E Gerweck, Rakesh K Jain, Dai Fukumura.   

Abstract

Normalization of tumor vasculature is an emerging strategy to improve cytotoxic therapies. Here we show that eliminating nitric oxide (NO) production from tumor cells via neuronal NO synthase silencing or inhibition establishes perivascular gradients of NO in human glioma xenografts in mice and normalizes the tumor vasculature, resulting in improved tumor oxygenation and response to radiation treatment. Creation of perivascular NO gradients may be an effective strategy for normalizing abnormal vasculature.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278052     DOI: 10.1038/nm1730

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  59 in total

Review 1.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Authors:  Shom Goel; Andus Hon-Kit Wong; Rakesh K Jain
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

2.  A Ratiometric Acoustogenic Probe for in Vivo Imaging of Endogenous Nitric Oxide.

Authors:  Christopher J Reinhardt; Effie Y Zhou; Michael D Jorgensen; Gina Partipilo; Jefferson Chan
Journal:  J Am Chem Soc       Date:  2018-01-09       Impact factor: 15.419

3.  Impaired lymphatic contraction associated with immunosuppression.

Authors:  Shan Liao; Gang Cheng; David A Conner; Yuhui Huang; Raju S Kucherlapati; Lance L Munn; Nancy H Ruddle; Rakesh K Jain; Dai Fukumura; Timothy P Padera
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

4.  Generation of nitric oxide gradients in microfluidic devices for cell culture using spatially controlled chemical reactions.

Authors:  Ying-Hua Chen; Chien-Chung Peng; Yung-Ju Cheng; Jin-Gen Wu; Yi-Chung Tung
Journal:  Biomicrofluidics       Date:  2013-11-07       Impact factor: 2.800

5.  SILAC-based proteomics of human primary endothelial cell morphogenesis unveils tumor angiogenic markers.

Authors:  Sara Zanivan; Federica Maione; Marco Y Hein; Juan Ramon Hernández-Fernaud; Pawel Ostasiewicz; Enrico Giraudo; Matthias Mann
Journal:  Mol Cell Proteomics       Date:  2013-08-26       Impact factor: 5.911

Review 6.  Lymphatic function and immune regulation in health and disease.

Authors:  Shan Liao; Timothy P Padera
Journal:  Lymphat Res Biol       Date:  2013-09-11       Impact factor: 2.589

Review 7.  Neurexins and neuroligins: synapses look out of the nervous system.

Authors:  Alessia Bottos; Alberto Rissone; Federico Bussolino; Marco Arese
Journal:  Cell Mol Life Sci       Date:  2011-03-11       Impact factor: 9.261

8.  NOS Inhibition Modulates Immune Polarization and Improves Radiation-Induced Tumor Growth Delay.

Authors:  Lisa A Ridnour; Robert Y S Cheng; Jonathan M Weiss; Sukhbir Kaur; David R Soto-Pantoja; Debashree Basudhar; Julie L Heinecke; C Andrew Stewart; William DeGraff; Anastasia L Sowers; Angela Thetford; Aparna H Kesarwala; David D Roberts; Howard A Young; James B Mitchell; Giorgio Trinchieri; Robert H Wiltrout; David A Wink
Journal:  Cancer Res       Date:  2015-05-19       Impact factor: 12.701

Review 9.  Nitric Oxide: The Forgotten Child of Tumor Metabolism.

Authors:  Bahar Salimian Rizi; Abhinav Achreja; Deepak Nagrath
Journal:  Trends Cancer       Date:  2017-08-18

10.  Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.

Authors:  Massimiliano Mazzone; Daniela Dettori; Rodrigo Leite de Oliveira; Sonja Loges; Thomas Schmidt; Bart Jonckx; Ya-Min Tian; Anthony A Lanahan; Patrick Pollard; Carmen Ruiz de Almodovar; Frederik De Smet; Stefan Vinckier; Julián Aragonés; Koen Debackere; Aernout Luttun; Sabine Wyns; Benedicte Jordan; Alberto Pisacane; Bernard Gallez; Maria Grazia Lampugnani; Elisabetta Dejana; Michael Simons; Peter Ratcliffe; Patrick Maxwell; Peter Carmeliet
Journal:  Cell       Date:  2009-02-12       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.